---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-017922"
form_type: "8-K"
ticker: "OM"
cik: "0001484612"
company_name: "Outset Medical, Inc."
filed_at: "2024-02-21T23:59:59+00:00"
generated_at: "2026-06-05T21:58:59.683882+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Outset Medical Q4 revenue $30.5M, FY revenue $130.4M; CCO Steve Williamson departs March 1

## Summary
- FY 2023 revenue $130.4M (+13% YoY); Q4 revenue $30.5M (-4.7% YoY) due to product revenue decline.
- Q4 gross margin 25.3% (non-GAAP 26.7%), up ~900 bps YoY; FY gross margin 22.2% (non-GAAP 23.6%).
- Tablo installed base 5,350 consoles exiting 2023; recurring revenue exceeded 50% of total revenue.
- 2024 guidance reaffirmed: revenue $145-153M (+12-18% YoY); non-GAAP gross margin low-30% range.
- CCO Steve Williamson to depart March 1, 2024 to become CEO of another public med device company; no dispute.

## SEC filing metadata
- accession: 0000950170-24-017922
- form_type: 8-K
- ticker: OM
- cik: 0001484612
- company_name: Outset Medical, Inc.
- filed_at: 2024-02-21T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1484612/000095017024017922/0000950170-24-017922-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1484612/000095017024017922/om-20240216.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-017922
- JSON: https://secwatch.observer/filing/0000950170-24-017922.json
- Plain text: https://secwatch.observer/filing/0000950170-24-017922.txt

## Key facts
- Earnings Releases
  Outset Medical, Inc. updated its fourth quarter and full year ended December 31, 2023 guidance (reaffirmed).
  - Period: fourth quarter and full year ended December 31, 2023
  - Guidance: reaffirmed
  - Result: reported results
  source text: On February 21, 2024, Outset Medical, Inc. (the “Company”) issued a press release and will hold its fourth quarter and full year 2023 earnings conference call announcing the Company’s financial results for the quarter and year ended December 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1484612/000095017024017922/0000950170-24-017922-index.htm
- Executive change
  Steve Williamson departed as Chief Commercial Officer at Outset Medical, Inc..
  - Action: depart
  - Role: Chief Commercial Officer
  source text: On February 16, 2024, Steve Williamson informed the Company of his decision to depart from the Company and his role as Chief Commercial Officer, effective March 1, 2024, to become the CEO of another publicly traded medical device company.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1484612/000095017024017922/0000950170-24-017922-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.